Back to top
more

Basilea Pharmaceutica (BPMUF)

(Delayed Data from OTC)

$44.45 USD

44.45
NA

+3.70 (9.08%)

Updated Apr 10, 2024 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BPMUF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Basilea Pharmaceutica AG [BPMUF]

Reports for Purchase

Showing records 1 - 20 ( 70 total )

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 1

04/22/2024

Company Report

Pages: 8

Need for innovation against severe infections

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 2

04/10/2024

Company Report

Pages: 2

CARB-X grant for preclinical programs

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 3

04/04/2024

Company Report

Pages: 6

Zevtera crosses key US regulatory hurdle

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 4

03/11/2024

Company Report

Pages: 2

Strong Cresemba traction triggers milestone payment

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 5

02/20/2024

Company Report

Pages: 11

From strength to strength

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 6

01/26/2024

Company Report

Pages: 2

Strong close to FY23 with another milestone payment

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 7

01/22/2024

Company Report

Pages: 6

Pipeline Overhauled; Debt Repayment Accelerated; Modulating PT to CHF85

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 8

01/17/2024

Company Report

Pages: 2

Antibiotic addition to further replenish pipeline

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 9

12/22/2023

Company Report

Pages: 14

Refilling the pipeline for growth

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 10

11/14/2023

Company Report

Pages: 2

Incremental acquisition to arsenal; new guidance

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 11

11/01/2023

Company Report

Pages: 2

Growth pivot with potential antibacterial addition

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 12

11/01/2023

Company Report

Pages: 5

License Option Inked on Novel Antibacterial Agent Tonabacase; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 13

10/20/2023

Company Report

Pages: 2

Antifungal addition to bolster pipeline

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 14

10/19/2023

Company Report

Pages: 5

Novel Antifungal Acquired, Bolstering Clinical Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 15

10/18/2023

Company Report

Pages: 2

New data support FDA application for ceftobiprole

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 16

10/03/2023

Company Report

Pages: 2

FDA accepts New Drug Application for ceftobiprole

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 17

10/02/2023

Company Report

Pages: 5

Ceftobiprole New Drug Application Accepted for FDA Review; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 18

09/29/2023

Company Report

Pages: 2

Zevtera (ceftobiprole) clinical data published

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 19

08/17/2023

Company Report

Pages: 7

A strong start to FY23 across the board

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 20

08/16/2023

Company Report

Pages: 5

Mid-Year Report Showcases Impressive Operating Progress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party